Cite

HARVARD Citation

    Dembla, V. et al. (2017). Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific reports. 7 (1), pp. 1-9. [Online]. 
  
Back to record